Single-center experience of perioperative treatment of liver transplantation for acute hepatic failure

doi:10.3969/j.issn.2095-4344.2014.36.001

Abstract

Abstract:

BACKGROUND: Perioperative treatment of emergency liver transplantation for acute hepatic failure is extremely different from common liver transplantation, due to complex conditions, high risk, several complications, and high mortality.
OBJECTIVE: To summarize the experience of emergency liver transplantation for acute hepatic failure during the perioperative period, and to increase the success rate in treatment of acute hepatic failure.
METHODS: A retrospective analysis was undertaken on the clinical data of 38 cases undergone emergency liver transplantation for acute hepatic failure. There were 21 male and 17 female, who aged 15-69 years. Among them, 23 cases had hepatitis B virus (including 2 cases with hepatitis B and C virus), 7 cases had Wilsons disease, 3 cases had mushroom poisoning, 2 cases had unknown liver damage, 1 case had Tripterygium wilfordii poisoning, 1 case had decompensation after partial liver resection due to trauma, and 1 case had liver transplantation from corpse.
RESULTS AND CONCLUSION: The survival time of the involve patients was 13-1 740 days, and the median survival time was 634 days. Perioperative survival rate was 76%, 1-year survival rate was 63%, and 2-year survival rate was 58%. During the perioperation nine cases died of brain edema and intracranial hypertension, renal failure, severe pulmonary infection, multiple organ failure, coagulation disorders (intracranial hemorrhage, upper digestive tract hemorrhage), acute respiratory distress syndrome and primary graft non-function. At present, emergency liver transplantation is still the most effective way for acute liver failure. Hemorrhage, infection and rejection are the leading causes of the death. Each perioperative treatment is of great significance for the success of liver transplantation and long-term survival.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: liver transplantation, liver failure, acute, survival rate

CLC Number:

R318

Pei Li-juan, Xu Hong-bin, Jin Xin, Shi Xian-jie. Single-center experience of perioperative treatment of liver transplantation for acute hepatic failure[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(36): 5741-5746.

Figures/Tables 1

References

[1] Polson J, Lee WM. American Association for the Study of Liver Disease. AASLD position paper: The management of Acute hepatic failure. Hepatology.2005;41(5):1179-1197.
[2] Bernal W, Wendon J. Liver transplantation in adults with acute liver failure. J Hepatol.2004;40(2):192-197.
[3] 中华医学会感染病学分会肝衰竭与人工肝学组、中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14:643-646.
[4] Satin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure：consensus recommendations ofthe Asian Pacific Associationfor the study ofthe liver(APASL). Hepatol Int.2009; 3:269-282.
[5] Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the study of Liver Diseases Position Paper on acute fiver failure 2011. Hepatology.2012;55: 965-967.
[6] AASLD Position Paper: The Management of Acute Liver Failure：Up-date 2011[EB/OL] (2011-09)E2011-01-02]. http://www.aasld.org/practiceguidelines/Documents/AcuteLiverFailureUpdate2011.
[7] 中华医学会感染病学分会肝衰竭与人工肝学组、中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南(2012版) [J].中华肝脏病杂志,2013,21:177-183.
[8] Sass DA. Shakil AO. Fulminant hepatic failure.Liver Transpl. 2005;11:594-605.
[9] Bretheriek AD, Craig DG, Masterton G, et al. Acute liver failure in Scotland between 1992 and 2009:incidence,aetiology and outcome.OJM.2011;104:945-956.
[10] 王建锋,李霄,韩炜,等.急性肝衰竭的治疗进展[J].中华肝胆外科杂志,2012,18(12):957-960.
[11] Achilles A, Robert S, Ronald W, et al. Prospective, randomized, multicenter, controlled trial of a bioartifical liver in treat acute liver failure.Ann of Surg,2004;239(5):660-670.
[12] Olyaei AJ, deMattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs : new insight and preventive strategies. Curr Opin Crit Care.2001;7(6):384-389.
[13] Shin HS, Kim SP, Han SH, et al. Prognostic indicators for acute liver failure development and mortality in patients with hepatitis a: consecutive case analysis. Yonsei Med J.2014; 55(4):953-959.
[14] Han YS, Lee SK, Joh JW, et al. outcomes of hepatitis B virus recurrence after liver transplantation. Transplant Proc. 2006; 38(7):2123-2124.
[15] Blei AT, Cordoba J. Practice Parameters Committee ofthe American College of Gastroenterology.Hepatic Encephalopathy. Am J Gastroenteml.2001;96:1968-1976.
[16] Pugh RN, MurrayLyon IM, Dawson JL, et al.Transection of the oesophagus for bleeding oesophageal varices.Br J Surg. 1973; 60:646-649.
[17] Kamath PS, Wiesner RH, Malinchoc M, et al A model tO predict survival in patients with end-stage liver disease.Hepatology.2001;33:464-470.
[18] Dhiman RK, Seth AK, Jain S, et al. Prognositic evaluation of early indicators in fulminant hepatic failure by multivariate analysis.Dig Dis Sci.1998;43:1311.
[19] 李兰娟.肝衰竭临床治疗中的难点和热点[J].中华肝脏病杂志，2012,20(6):405-407.
[20] Voigt MD. Predicting Death in Patients With Acetamin-ophen-Induced Acute Liver Failure：The King’s College Hospital Model Is on the SOFA，Not the Mat．Liver Transpl.2012;18:384-386.
[21] Kamath PS, Kim WR. The model for end-stage 1iver disease (MELD). Hepatology.2007;45:797-805.
[22] Mochida S．Indication criteria for liver transplantation for acute fiver failure in Japan.Hepatol Res.2008;38 Suppl l:S52-55.
[23] 饶慧瑛,郭芳,魏来.2005年美国肝病学会急性肝衰竭诊治和肝移植患者评价指南简介[J].中华肝脏病杂志,2006,14(2):154-156.
[24] Jain S, Pendyala P, Varma S, et al.Effect of renal dysfunction in fulminant hepatic failure. Trop Gastro.2000;21(3):118-120.
[25] Patrono D, Brunati A, Romagnoli R, et al. Liver transplantation after severe hepatic trauma: a sustainable practice. A single-center experience and review of the literature.Clin Transplant.2013;27(4):E528-37.
[26] Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med.1993;21(3):328-338.
[27] Ostapowicz GA, Fontana RJ, Schi odt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med.2002;137(12): 947-954.
[28] Karidis NP, Kouraklis G, Theocharis SE. Platelet activating factor in liver injury: a relational scope. World J Gastroenter ol. 2006;12(23):3695-3706.
[29] Jung O, Asbe Vollkopf A, Betz C, et al. Long term therapy of acute liver failure to successful transplantation with an extra corporealliver support system. Gastroenterol.2007; 45(1):21.
[30] Steadman RH, Van Rensburg A, KrRnler DJ. Transplantation for acute liver failure：perioperative management.Curt Opin Organ Transplant.2010;15:368-373.
[31] Mochida S.Indication criteria for liver transplantation for acute fiver failure in Japan.Hepatol Res.2008;38 Suppl l:S52-55.
[32] Ling Q, Xu X, Wei Q, et al. Downgrading MELD improves the outcomes after liver transplantation in patients with acute-on-chronic hepatitis B liver failure.PLoS One.2012;7: e30322.
[33] Fontana RJ, Ellerbe C, Durkalski VE, et al.Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study. Liver Int. 2014 Jul 12.[Epub ahead of print]
[34] Manka P, Olliges V, Bechmann LP,et al.Low levels of blood lipids are associated with etiology and lethal outcome in acute liver failure.PLoS One. 2014;9(7):e102351.
[35] Sampaio MS, Martin P, Bunnapradist S.Renal Dysfunction in End-Stage Liver Disease and Post-Liver Transplant.Clin Liver Dis. 2014;18(3):543-560.
[36] Shin HS, Kim SP, Han SH,et al.Prognostic indicators for acute liver failure development and mortality in patients with hepatitis a: consecutive case analysis.Yonsei Med J. 2014; 55(4): 953-959.
[37] Kaido T, Tomiyama K, Ogawa K,et al.Section 12. Living donor liver transplantation for patients with high model for end-stage liver disease scores and acute liver failure.Transplantation. 2014; 97 Suppl 8:S46-7.
[38] Wu FL, Shi KQ, Chen YP,et al.Scoring systems predict the prognosis of acute-on-chronic hepatitis B liver failure: an evidence-based review.Expert Rev Gastroenterol Hepatol. 2014;8(6):623-632.
[39] Koch A, Zimmermann HW, Gassler N, et al.Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure. Liver Int. 2014 Feb 28. [Epub ahead of print].
[40] Zheng YB, Huang ZL, Wu ZB,et al.Dynamic changes of clinical features that predict the prognosis of acute-on-chronic hepatitis B liver failure: a retrospective cohort study.Int J Med Sci. 2013;10(12):1658-1664.